One of the things I often wonder about is there are tons of Biotechs with NOLs the equivalent of POIEs. Why aren't they adopting a similar strategy? Seems like the market is ripe for professional NOL brokers to operate matching up losing and winning companies. It will be interesting to see who the players were who turn out to be instrumental in PIOEs transaction. I'm guessing L210 will have played a significant role beyond investing and lending.